Charity’s concern over NICE osteoporosis guidance

Second-line treatment for osteoporosis will be difficult to prescribe under final recommendations from NICE, says a leading charity.

Final appraisal documents on primary and secondary prevention for osteoporosis means that those unable to tolerate first-line generic alendronate will have to get worse to qualify for risedronate and etidronate.

A quarter of patients are unable to take alendronate, according to the National Osteoporosis Society (NOS).

Under the guidelines, patients with a T-score of -2.5 standard deviation or below are eligible for alendronate. But those intolerant to alendronate need higher T-scores to qualify for second-line treatments.

Last year, the NOS appealed against the draft appraisals which recommended alendronate as the only treatment.

‘We had hoped for real progress after our successful appeal against its previous drug appraisal,' said Nick Rijke, public and external affairs director for the NOS.

‘But NICE has now published something that does not overcome the shortcomings of its previous work - if anything this makes this worse for many thousands of patients.'

rachel.liddle@haymarket.com

National Institute for Health and Clinical Excellence guidelines

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus